Qualitative Interviews with Triple-Negative Breast Cancer Patients
Research type
Research Study
Full title
Qualitative Interviews with Patients with Triple-Negative Breast Cancer (TNBC)
IRAS ID
271972
Contact name
Duncan Wheatley
Contact email
Sponsor organisation
AstraZeneca US
Clinicaltrials.gov Identifier
N/A, N/A
Duration of Study in the UK
0 years, 2 months, 31 days
Research summary
IQVIA (www.iqvia.com), a healthcare research firm, is currently conducting a qualitative research study with patients who have been diagnosed with Triple-Negative Breast Cancer (TNBC) by their physician. The purpose of the study is to explore patients’ experiences with TNBC (identify the signs, symptoms, and impacts of the disease and its treatments) that are important and relevant to patients with TNBC. The study will be conducted with the intent to update a Conceptual Model designed to appropriately capture and measure the key signs, symptoms, and impacts of TNBC disease.
The research will involve TNBC patients participating in a telephone interview lasting 60-90-minutes. Upon completion of the interview, patients will be compensated with a payment at fair market value paid by Sponsor (£125 for UK patients). The study is strictly for research purposes; there will be no sales or promotional activities.
REC name
London - City & East Research Ethics Committee
REC reference
19/LO/1653
Date of REC Opinion
6 Dec 2019
REC opinion
Favourable Opinion